";s:4:"text";s:5898:" Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.Alliance for Regenerative Medicine: The Alliance for Regenerative Medicine Releases List of Presenting Companies at the 2020The Alliance for Regenerative Medicine Releases List of Presenting Companies at the 2020 Cell & Gene Meeting on the MesaAgenus To Participate in a Panel on Cell Therapy for Infectious Diseases at the B. Riley Virtual Infectious Disease SummitPluristem CEO Issues Shareholder Update on Clinical ProgramsTodos Medical Ltd.: Todos Medical Expands Management Team and Advisory BoardTodos Medical Expands Management Team and Advisory BoardPluristem Announces Activation of Clinical Sites and Commencement of Patient Enrollment in U.S. FDA Phase II COVID-19 ARDSPluristem Joins Forces with CRISPR-IL National Consortium to Advance Development of Cutting-Edge Genome Editing Solutions forPluristem Provides 28-Day Follow Up for Ventilator-Dependent COVID-19 Patients under Compassionate Use Program in Israel andU.S. Only 4.90% of the stock of Pluristem Therapeutics is held by insiders. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. Haifa, 31905 Pluristem Therapeutics has a P/B Ratio of 6.15. Pluristem Therapeutics Inc. (NASDAQ:PSTI)Earnings for Pluristem Therapeutics are expected to grow in the coming year, from ($1.49) to ($1.12) per share. Get the latest Pluristem Therapeutics, Inc. PSTI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. IsraelAlliance for Regenerative Medicine: The Alliance for Regenerative Medicine Releases List of Presenting Companies at the 2020The Alliance for Regenerative Medicine Releases List of Presenting Companies at the 2020 Cell & Gene Meeting on the MesaAgenus To Participate in a Panel on Cell Therapy for Infectious Diseases at the B. Riley Virtual Infectious Disease SummitPluristem CEO Issues Shareholder Update on Clinical ProgramsTodos Medical Ltd.: Todos Medical Expands Management Team and Advisory BoardTodos Medical Expands Management Team and Advisory BoardPluristem Announces Activation of Clinical Sites and Commencement of Patient Enrollment in U.S. FDA Phase II COVID-19 ARDSPluristem Joins Forces with CRISPR-IL National Consortium to Advance Development of Cutting-Edge Genome Editing Solutions forPluristem Provides 28-Day Follow Up for Ventilator-Dependent COVID-19 Patients under Compassionate Use Program in Israel andU.S. FDA Clears Pluristem’s IND Application for Phase II COVID-19 StudyWork From Home: How IBM Balances Business, Employee NeedsMatam Advanced Technology Park Pluristem Therapeutics does not have a long track record of dividend growth.In the past three months, Pluristem Therapeutics insiders have not sold or bought any company stock. Earnings and Valuation of Pluristem Therapeutics Inc. (NASDAQ:PSTI. Building 20 The high price target for PSTI is $15.50 and the low price target for PSTI is $12.00.
For the fiscal year ending Jun 2020 , the consensus EPS* forecast has remained the same over the past week at -1.49 and decreased over the past month from -1.36 to -1.49(9.56%).
Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18.
It focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. There are currently 5 buy ratings for the stock, resulting in a consensus rating of “Buy.”Pluristem Therapeutics has received a consensus rating of Buy. Only 7.82% of the stock of Pluristem Therapeutics is held by institutions.has been editor at a well established media. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. His background is IT but had a passion to write about Business, Politics and Technology. Pluristem Therapeutics, Inc. engages in cell therapy development. Only 7.82% of the stock of Pluristem Therapeutics is held by institutions. The P/E ratio of Pluristem Therapeutics is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Pluristem Therapeutics Inc. stock is up 100.00% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives PSTI stock a score of 74 out of a possible 100.. That rank is primarily influenced by a long-term technical score of 81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Their average twelve-month price target is $12.88, suggesting that the stock has a possible upside of 46.31%.
For the fiscal quarter endingMar 2020 , the consensus EPS* forecast has remained the same over the past week at -0.29 and decreased over the past month from -0.25 to -0.29(16.00%). The P/E ratio of Pluristem Therapeutics is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. none raised and none lowered their forecast.5 Wall Street analysts have issued ratings and price targets for Pluristem Therapeutics in the last 12 months.
